Clinical trial navigation is a clinical access problem
Clinical trial enrollment in rare cancers remains stubbornly low. In T-cell lymphomas, a heterogeneous group of over a dozen distinct subtypes affecting roughly 9,000 new patients annually in the United States, fewer than 7 percent of eligible patients participate in clinical trials. This statistic has persisted for decades despite growing recognition of the problem by professional societies, advocacy organizations, and regulatory agencies.
The conventional explanation focuses on awareness. Patients don’t know …
Clinical trial navigation is a clinical access problem
